Developer docs
API playgroundTry for free, no card

Search company profiles

Qkine

Full company profile

uuid0002aww

Namestring
Qkine
Legal namestring
Qkine Ltd
Websiteurl
qkine.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Qkine is a Cambridge, UK-based specialist manufacturer of high-purity, animal-free recombinant growth factors, cytokines and complex bioactive proteins for life science research and cell therapy applications. The company operates from a single ISO 9001:2015-certified facility at Murdoch House, Cambridge, and produces its catalog using an E. coli-based expression platform engineered to deliver complete absence of animal-derived contaminants, lot-to-lot bioactivity consistency and ultra-high purity. Its portfolio spans the FGF, TGF-β, EGF, HGF, IGF, neurotrophin, PDGF, R-spondin and interleukin families, complemented by differentiated engineered variants such as the thermostable FGF2-G3 and the patent-pending optimized IL-34 PLUS sequence (GB 2514413.0), as well as ECM and plate-format consumables (QkPlate vitronectin plates) and distributed third-party media supplements (Defined Bioscience HiDef line, StemCultures DISC hydrogels).

The company serves four primary customer segments: stem cell and organoid researchers, cell and gene therapy manufacturers, cellular agriculture companies, and emerging technology developers working in organ-on-a-chip and bioprinting. Its go-to-market blends direct e-commerce through qkine.com, a 35+ country distributor network, and high-value enterprise channels including a multi-year supply and distribution agreement with BioLife Solutions for worldwide cell and gene therapy customers, a strategic partnership with Akron Bio for GMP manufacturing, reciprocal distribution with Pluristyx for clinical-grade iPSC workflows, and Canadian distribution via Cedarlane. Products are priced per unit (typically per microgram), with research-grade SKUs in the low hundreds of pounds and cell therapy grade GMP-equivalent SKUs commanding £3,000–£5,000 per 500–1,000 µg.

Qkine was founded in 2016 and has raised approximately £7–8 million across eight funding rounds from 2018 through December 2022, led by Parkwalk Advisors and Downing Ventures, with participation from O2h Ventures, Martlet Capital, Cambridge Angels and the University of Cambridge Enterprise. The company is privately held (Qkine Ltd, registered in England and Wales), employs between 11 and 50 people, and is in an active commercial expansion phase evidenced by seven strategic announcements in 2026 alone spanning new product launches, channel partnerships, and geographic entry into Canada.

Short descriptiontext

Qkine is a Cambridge, UK-based manufacturer of high-purity, animal-free recombinant growth factors and cytokines for stem cell, organoid, cell and gene therapy, and cellular agriculture applications, serving academic and biopharma customers across 35+ countries via direct sales and global distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant proteins, growth factors, cell culture reagents, stem cell research, cellular agriculture
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Recombinant Proteins
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Recombinant Protein Sales
TypeOne Time License
Description

Qkine generates revenue through the sale of recombinant growth factors, cytokines, and complex bioactive proteins. Products are sold in various unit sizes with pricing ranging from hundreds to thousands of pounds per unit. Both research use and cell therapy grade products are available.

qkine.com
2Distribution Partnership Revenue
TypeOne Time License
Description

Revenue from distribution agreements with partners like Defined Bioscience for media supplements, and co-development products with StemCultures. Qkine distributes third-party products alongside its own manufactured proteins.

qkine.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details3 tiers
1Recombinant human IL-34 PLUS protein (Qk091) research grade
ModelUnit PricingBilling cadencePay-as-you-go
Notes

£350.00 for 25 µg, £4,500.00 for 1,000 µg. Prices exclude VAT and delivery charges.

qkine.com
2QkPlate human vitronectin coated plates (Qk2001)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

£135.00 for 5 plates, £400.00 for 20 plates. Pack size 5 plates per pack.

qkine.com
3Recombinant human activin A cell therapy grade (Qk001-CTG)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

£3,035.00 for 500 µg, £4,785.00 for 1,000 µg. Premium pricing for cell therapy grade GMP-equivalent products.

qkine.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1StemCultures
Description

Co-developed products with StemCultures featuring hydrogel DISC technology for controlled growth factor release

qkine.com
+2 more records
Core offering1 text field

Qkine manufactures and sells high-purity, animal-free recombinant growth factors, cytokines, and complex bioactive proteins produced in an E. coli expression system in their ISO 9001:2015-certified Cambridge facility. The portfolio serves stem cell maintenance and differentiation, organoid culture, cellular agriculture, and cell and gene therapy manufacturing, with both research-grade and cell therapy grade (GMP-equivalent) offerings.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Qkine TGF-β1 PLUS was found to be more bioactive than mammalian-expressed TGF-β1 from alternative suppliers
+2 more records
Product and service9 records
1Recombinant growth factors and cytokines
CategoryRecombinant Proteins / Cell Culture Reagents
Description

High-purity, animal-free recombinant growth factors and cytokines spanning the TGF-β superfamily, FGF superfamily, EGF family, neurotrophins, interleukins, R-spondins, PDGF family, HGF family, IGF family, colony stimulating factors, and extracellular matrix proteins, designed for stem cell maintenance, differentiation, organoid culture, and other life science applications.

2Cell and gene therapy grade proteins
CategoryCell and Gene Therapy Reagents
Description

Cell therapy grade recombinant proteins (e.g., recombinant human activin A cell therapy grade Qk001-CTG) manufactured as GMP grade equivalents with defined quality criteria, comprehensive documentation, and traceability for use in cell and gene therapy manufacturing and clinical production.

3Discovery and differentiation kits
CategoryCell Culture Kits
Description

Curated kits of Qkine growth factors and cytokines designed to streamline discovery workflows and directed differentiation of stem cells into specific lineages for research applications.

4QkPlate vitronectin coated plates
CategoryExtracellular Matrix / Coated Plates
Description

Pre-prepared dried human vitronectin-coated 6-well plates (Qk2001) enabling room-temperature storage and reproducible iPSC maintenance and differentiation, with additional formats planned.

5Encapsulated growth factors (StemCultures co-developed products)
CategoryEncapsulated Growth Factors
Description

Encapsulated growth factor products combining Qkine high-purity proteins with StemCultures' hydrogel DISC technology for controlled growth factor release, improving reproducibility and scalability of 2D and 3D cell cultures.

6Food grade growth factor proteins
CategoryCellular Agriculture Reagents
Description

High-quality food grade recombinant growth factor proteins developed for cultivated meat and other cellular agriculture applications requiring defined, animal-free, and scalable raw materials.

7Recombinant GDF-11 (BMP-11) and activin AB proteins
CategoryRecombinant Proteins / Cell Culture Reagents
Description

Newly launched recombinant GDF-11 (Qk126) and activin AB (Qk127) proteins from the TGF-β superfamily, offered for cell growth, survival, and differentiation research applications.

8Defined Bioscience cell culture media supplements (distribution)
CategoryCell Culture Media Supplements
Description

Distributed cell culture media supplements including HiDef B8 stem cell growth medium, Ready-CEPT cell viability supplement, HiDef N-2 neural medium supplement, and HiDef ITS cell culture supplement, supplied by Qkine outside the US to complement its animal-free growth factor portfolio.

9IL-34 PLUS optimized recombinant protein
CategoryRecombinant Proteins / Cytokines
Description

Recombinant human IL-34 PLUS protein (Qk091) manufactured using a Qkine-optimized sequence (patent pending GB 2514413.0) that delivers highly and consistently superior bioactivity compared to mammalian and bacterially expressed alternatives.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-22
Description

Distribution agreement for Defined Bioscience's animal-free cell culture media supplements. Qkine supplies these products outside the US. Perfect pairing with Qkine's animal-free growth factors, cytokines and adhesion proteins.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Reciprocal distribution agreement pairing Pluristyx's proprietary iPSC lines with Qkine's ultra-pure, bioactive proteins. Companies offer a 'ready-to-use' solution for improved experimental consistency, reduced development timelines, and seamless transition from discovery to clinical applications.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Official distributor of Qkine products in Canada. Cedarlane is a long-standing presence in the life science research community with ISO 9001:2015 and ISO 13485:2016 certification.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-12
Description

Multi-year supply and distribution agreement. BioLife received exclusive worldwide distribution rights for specific Qkine cytokine products and non-exclusive rights in the broader CGT market. Companies collaborate on packaging Qkine products using BioLife's CellSeal Connect vial system.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Strategic partnership combining Qkine's growth factor and cytokine technologies with Akron's GMP manufacturing capabilities. Aims to accelerate development and delivery of innovative, high-performance recombinant proteins for stem cell expansion, differentiation, and maturation in regenerative medicine.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Co-developed products combining Qkine's high-purity growth factors with StemCultures' hydrogel DISC technology for controlled growth factor release. Products improve reproducibility and scalability of 2D and 3D cell cultures.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Acquired by Thermo Fisher in 2022, PeproTech is the dominant recombinant growth factor and cytokine supplier and directly competes with Qkine in research-grade and GMP-grade proteins for stem cell, immunology, and cell therapy applications.

TypeBroad incumbent
Description

R&D Systems is one of the largest recombinant protein catalogs globally, supplying growth factors and cytokines for stem cell, organoid, and cell therapy research. Bio-Techne's scale, GMP capabilities, and expansive catalog make it a primary incumbent competitor.

TypeDirect peer
Description

Miltenyi Biotec manufactures GMP-grade cytokines and growth factors specifically for cell and gene therapy manufacturing, directly overlapping with Qkine's cell therapy-grade protein portfolio. Strong distribution in Europe and established CGT customer relationships make it a key competitor.

TypeDirect peer
Description

CellGenix specializes in GMP-manufactured cytokines and growth factors for cell and gene therapy and regenerative medicine. Their portfolio and target customer base (CGT manufacturers) overlap almost exactly with Qkine's cell therapy-grade product line.

TypeBroad incumbent
Description

Stemcell Technologies offers a comprehensive portfolio of cell culture media, growth factors, and reagents for stem cell and organoid research. While a broader portfolio than Qkine, it competes directly in stem cell and organoid reagent markets.

TypeEmerging player
Description

ACROBiosystems is a fast-growing recombinant protein supplier offering a broad catalog of cytokines and growth factors at competitive prices. While it competes mainly in research-grade segments, its scale and pricing pressure make it a credible emerging threat.

TypeEmerging player
Description

Sino Biological manufactures recombinant proteins including growth factors and cytokines for research and emerging cell therapy applications. Aggressive pricing and growing catalog create competitive pressure on research-grade protein pricing across the industry.

TypeBroad incumbent
Description

ReproCELL (now part of Fujifilm) supplies reagents and services for stem cell research and regenerative medicine, with growth factor offerings overlapping with Qkine's stem cell maintenance and differentiation protein portfolio.

TypeDirect peer
Description

Akron Bio manufactures GMP cytokines and ancillary materials for cell and gene therapy. Qkine's January 2026 strategic partnership with Akron combines their GMP manufacturing with Qkine's growth factor technology, making Akron both a competitor and collaborator in the CGT cytokines space.

TypeEmerging player
Description

Defined Bioscience supplies defined, animal-free cell culture media supplements for stem cell and regenerative medicine applications. While focused on media supplements rather than proteins, their complementary product positioning led Qkine to enter a distribution agreement for non-US markets in 2026.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qkine

Recombinant Proteinsqkine.com

Qkine is a Cambridge, UK-based manufacturer of high-purity, animal-free recombinant growth factors and cytokines for stem cell, organoid, cell and gene therapy, and cellular agriculture applications, serving academic and biopharma customers across 35+ countries via direct sales and global distributors.

What Qkine does

Qkine is a Cambridge, UK-based specialist manufacturer of high-purity, animal-free recombinant growth factors, cytokines and complex bioactive proteins for life science research and cell therapy applications. The company operates from a single ISO 9001:2015-certified facility at Murdoch House, Cambridge, and produces its catalog using an E. coli-based expression platform engineered to deliver complete absence of animal-derived contaminants, lot-to-lot bioactivity consistency and ultra-high purity. Its portfolio spans the FGF, TGF-β, EGF, HGF, IGF, neurotrophin, PDGF, R-spondin and interleukin families, complemented by differentiated engineered variants such as the thermostable FGF2-G3 and the patent-pending optimized IL-34 PLUS sequence (GB 2514413.0), as well as ECM and plate-format consumables (QkPlate vitronectin plates) and distributed third-party media supplements (Defined Bioscience HiDef line, StemCultures DISC hydrogels).

The company serves four primary customer segments: stem cell and organoid researchers, cell and gene therapy manufacturers, cellular agriculture companies, and emerging technology developers working in organ-on-a-chip and bioprinting. Its go-to-market blends direct e-commerce through qkine.com, a 35+ country distributor network, and high-value enterprise channels including a multi-year supply and distribution agreement with BioLife Solutions for worldwide cell and gene therapy customers, a strategic partnership with Akron Bio for GMP manufacturing, reciprocal distribution with Pluristyx for clinical-grade iPSC workflows, and Canadian distribution via Cedarlane. Products are priced per unit (typically per microgram), with research-grade SKUs in the low hundreds of pounds and cell therapy grade GMP-equivalent SKUs commanding £3,000–£5,000 per 500–1,000 µg.

Qkine was founded in 2016 and has raised approximately £7–8 million across eight funding rounds from 2018 through December 2022, led by Parkwalk Advisors and Downing Ventures, with participation from O2h Ventures, Martlet Capital, Cambridge Angels and the University of Cambridge Enterprise. The company is privately held (Qkine Ltd, registered in England and Wales), employs between 11 and 50 people, and is in an active commercial expansion phase evidenced by seven strategic announcements in 2026 alone spanning new product launches, channel partnerships, and geographic entry into Canada.

Qkine firmographics

Firmographics
Name
Qkine
Legal name
Qkine Ltd
Website
https://qkine.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Qkine is a Cambridge, UK-based manufacturer of high-purity, animal-free recombinant growth factors and cytokines for stem cell, organoid, cell and gene therapy, and cellular agriculture applications, serving academic and biopharma customers across 35+ countries via direct sales and global distributors.
Ownership category
akta.pro rank

Qkine industry classification

Industry
Product category
Recombinant Proteins
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Recombinant proteins
  • Growth factors
  • Cell culture reagents
  • Stem cell research
  • Cellular agriculture

Where Qkine is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Qkine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Recombinant Protein Sales: Qkine generates revenue through the sale of recombinant growth factors, cytokines, and complex bioactive proteins. Products are sold in various unit sizes with pricing ranging from hundreds to thousands of pounds per unit. Both research use and cell therapy grade products are available.
  2. Distribution Partnership Revenue: Revenue from distribution agreements with partners like Defined Bioscience for media supplements, and co-development products with StemCultures. Qkine distributes third-party products alongside its own manufactured proteins.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goRecombinant human IL-34 PLUS protein (Qk091) research grade
Unit PricingPay-as-you-goQkPlate human vitronectin coated plates (Qk2001)
Unit PricingPay-as-you-goRecombinant human activin A cell therapy grade (Qk001-CTG)

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Qkine product offering

Product offering

Core offering

Qkine manufactures and sells high-purity, animal-free recombinant growth factors, cytokines, and complex bioactive proteins produced in an E. coli expression system in their ISO 9001:2015-certified Cambridge facility. The portfolio serves stem cell maintenance and differentiation, organoid culture, cellular agriculture, and cell and gene therapy manufacturing, with both research-grade and cell therapy grade (GMP-equivalent) offerings.

Differentiator

Problem solved

Functional benefit

Brands

  • StemCultures: Co-developed products with StemCultures featuring hydrogel DISC technology for controlled growth factor release
  • QkPlate
  • HiDef

Products and services

  • Recombinant growth factors and cytokines High-purity, animal-free recombinant growth factors and cytokines spanning the TGF-β superfamily, FGF superfamily, EGF family, neurotrophins, interleukins, R-spondins, PDGF family, HGF family, IGF family, colony stimulating factors, and extracellular matrix proteins, designed for stem cell maintenance, differentiation, organoid culture, and other life science applications.
  • Cell and gene therapy grade proteins Cell therapy grade recombinant proteins (e.g., recombinant human activin A cell therapy grade Qk001-CTG) manufactured as GMP grade equivalents with defined quality criteria, comprehensive documentation, and traceability for use in cell and gene therapy manufacturing and clinical production.
  • Discovery and differentiation kits Curated kits of Qkine growth factors and cytokines designed to streamline discovery workflows and directed differentiation of stem cells into specific lineages for research applications.
  • QkPlate vitronectin coated plates Pre-prepared dried human vitronectin-coated 6-well plates (Qk2001) enabling room-temperature storage and reproducible iPSC maintenance and differentiation, with additional formats planned.
  • Encapsulated growth factors (StemCultures co-developed products) Encapsulated growth factor products combining Qkine high-purity proteins with StemCultures' hydrogel DISC technology for controlled growth factor release, improving reproducibility and scalability of 2D and 3D cell cultures.
  • Food grade growth factor proteins High-quality food grade recombinant growth factor proteins developed for cultivated meat and other cellular agriculture applications requiring defined, animal-free, and scalable raw materials.
  • Recombinant GDF-11 (BMP-11) and activin AB proteins Newly launched recombinant GDF-11 (Qk126) and activin AB (Qk127) proteins from the TGF-β superfamily, offered for cell growth, survival, and differentiation research applications.
  • Defined Bioscience cell culture media supplements (distribution) Distributed cell culture media supplements including HiDef B8 stem cell growth medium, Ready-CEPT cell viability supplement, HiDef N-2 neural medium supplement, and HiDef ITS cell culture supplement, supplied by Qkine outside the US to complement its animal-free growth factor portfolio.
  • IL-34 PLUS optimized recombinant protein Recombinant human IL-34 PLUS protein (Qk091) manufactured using a Qkine-optimized sequence (patent pending GB 2514413.0) that delivers highly and consistently superior bioactivity compared to mammalian and bacterially expressed alternatives.

Quantifiable outcome

  • Qkine TGF-β1 PLUS was found to be more bioactive than mammalian-expressed TGF-β1 from alternative suppliers
  • +2 more outcomes

Companies that use Qkine

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Qkine technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Qkine partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered strategic, minor and core.

  • Defined BiosciencestrategicChannel Partner/ Reseller/ Distributor · 22 June 2026Distribution agreement for Defined Bioscience's animal-free cell culture media supplements. Qkine supplies these products outside the US. Perfect pairing with Qkine's animal-free growth factors, cytokines and adhesion proteins.
  • PluristyxstrategicStrategic or Co-development Partner · 1 May 2026Reciprocal distribution agreement pairing Pluristyx's proprietary iPSC lines with Qkine's ultra-pure, bioactive proteins. Companies offer a 'ready-to-use' solution for improved experimental consistency, reduced development timelines, and seamless transition from discovery to clinical applications.
  • CedarlaneminorChannel Partner/ Reseller/ Distributor · 1 April 2026Official distributor of Qkine products in Canada. Cedarlane is a long-standing presence in the life science research community with ISO 9001:2015 and ISO 13485:2016 certification.
  • BioLife SolutionscoreChannel Partner/ Reseller/ Distributor · 12 February 2026Multi-year supply and distribution agreement. BioLife received exclusive worldwide distribution rights for specific Qkine cytokine products and non-exclusive rights in the broader CGT market. Companies collaborate on packaging Qkine products using BioLife's CellSeal Connect vial system.
  • Akron BiostrategicStrategic or Co-development Partner · 27 January 2026Strategic partnership combining Qkine's growth factor and cytokine technologies with Akron's GMP manufacturing capabilities. Aims to accelerate development and delivery of innovative, high-performance recombinant proteins for stem cell expansion, differentiation, and maturation in regenerative medicine.
  • StemCulturesstrategicStrategic or Co-development PartnerCo-developed products combining Qkine's high-purity growth factors with StemCultures' hydrogel DISC technology for controlled growth factor release. Products improve reproducibility and scalability of 2D and 3D cell cultures.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Qkine competitors and assessment

Company assessment

Broad incumbents

  • PeproTech (Thermo Fisher Scientific): Acquired by Thermo Fisher in 2022, PeproTech is the dominant recombinant growth factor and cytokine supplier and directly competes with Qkine in research-grade and GMP-grade proteins for stem cell, immunology, and cell therapy applications.
  • R&D Systems (Bio-Techne): R&D Systems is one of the largest recombinant protein catalogs globally, supplying growth factors and cytokines for stem cell, organoid, and cell therapy research. Bio-Techne's scale, GMP capabilities, and expansive catalog make it a primary incumbent competitor.
  • Stemcell Technologies: Stemcell Technologies offers a comprehensive portfolio of cell culture media, growth factors, and reagents for stem cell and organoid research. While a broader portfolio than Qkine, it competes directly in stem cell and organoid reagent markets.
  • ReproCELL (Fujifilm): ReproCELL (now part of Fujifilm) supplies reagents and services for stem cell research and regenerative medicine, with growth factor offerings overlapping with Qkine's stem cell maintenance and differentiation protein portfolio.

Direct peers

  • Miltenyi Biotec: Miltenyi Biotec manufactures GMP-grade cytokines and growth factors specifically for cell and gene therapy manufacturing, directly overlapping with Qkine's cell therapy-grade protein portfolio. Strong distribution in Europe and established CGT customer relationships make it a key competitor.
  • CellGenix: CellGenix specializes in GMP-manufactured cytokines and growth factors for cell and gene therapy and regenerative medicine. Their portfolio and target customer base (CGT manufacturers) overlap almost exactly with Qkine's cell therapy-grade product line.
  • Akron Bio: Akron Bio manufactures GMP cytokines and ancillary materials for cell and gene therapy. Qkine's January 2026 strategic partnership with Akron combines their GMP manufacturing with Qkine's growth factor technology, making Akron both a competitor and collaborator in the CGT cytokines space.

Emerging players

  • ACROBiosystems: ACROBiosystems is a fast-growing recombinant protein supplier offering a broad catalog of cytokines and growth factors at competitive prices. While it competes mainly in research-grade segments, its scale and pricing pressure make it a credible emerging threat.
  • Sino Biological: Sino Biological manufactures recombinant proteins including growth factors and cytokines for research and emerging cell therapy applications. Aggressive pricing and growing catalog create competitive pressure on research-grade protein pricing across the industry.
  • Defined Bioscience: Defined Bioscience supplies defined, animal-free cell culture media supplements for stem cell and regenerative medicine applications. While focused on media supplements rather than proteins, their complementary product positioning led Qkine to enter a distribution agreement for non-US markets in 2026.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Qkine social profiles

Digital presence

Qkine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qkine leadership team

Management profile

Number of profiles

Profiles1 record

Qkine funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qkine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qkine

What does Qkine do?

Qkine manufactures and sells high-purity, animal-free recombinant growth factors, cytokines, and complex bioactive proteins produced in an E. coli expression system in their ISO 9001:2015-certified Cambridge facility. The portfolio serves stem cell maintenance and differentiation, organoid culture, cellular agriculture, and cell and gene therapy manufacturing, with both research-grade and cell therapy grade (GMP-equivalent) offerings.

Is Qkine a public or private company?

Qkine is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qkine founded?

Qkine was founded in 2016. It employs 11 to 50 people.

Where is Qkine based?

Qkine is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Qkine make money?

Two revenue lines are on record. Recombinant Protein Sales are the primary driver. The others are distribution Partnership Revenue.

Who are Qkine's main competitors?

Broad incumbents on record are PeproTech (Thermo Fisher Scientific), R&D Systems (Bio-Techne), Stemcell Technologies and ReproCELL (Fujifilm). Direct peers are Miltenyi Biotec, CellGenix and Akron Bio. Emerging players are ACROBiosystems, Sino Biological and Defined Bioscience.

Does Qkine have an API?

No public API is recorded for Qkine.

What industry is Qkine in?

Qkine's product category is Recombinant Proteins. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioinformantRoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. CustomersRoosterBio, Inc. announced a distribution agreement with Qkine Ltd., a Cambridge, UK-based manufacturer of high-purity recombinant growth factors and cytokines, allowing U.S. customers to order Qkine's full product range directly from RoosterBio. The partnership positions RoosterBio as a one-stop source for cell therapy and exosome developers seeking streamlined access to critical raw materials including cells, bioprocess media, and growth factors from a single U.S.-based supplier. RoosterBio will also integrate Qkine's translation-friendly recombinant proteins into its product and process solutions for pluripotent stem cells.PR NewswireRoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. CustomersRoosterBio and Qkine announced a distribution agreement giving US customers a single source for Qkine's recombinant growth factors and cytokines. The partnership makes RoosterBio a one-stop source for cell therapy and exosome developers, with Qkine's RUO products available now. The companies aim to support translation-ready workflows for advanced therapies.GlobeNewswirePluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)Pluristyx and Qkine announced a distribution agreement to support iPSC differentiation workflows. The partnership pairs Pluristyx's clinical-grade iPSC lines with Qkine's animal-free growth factors, aiming to improve consistency and reduce development timelines. The collaboration targets researchers and therapeutic developers in regenerative medicine.BioSpacePluristyx and Qkine Announce a Reciprocal Distribution Agreement in Support of Optimized Growth Factor Differentiation of Induced Pluripotent Stem Cell (iPSC)Pluristyx and Qkine announced a distribution agreement to support iPSC differentiation, pairing Pluristyx's clinical-grade iPSC lines with Qkine's animal-free growth factors. The partnership aims to improve experimental consistency, reduce development timelines, and enable a seamless transition from discovery to clinical applications.Simply Wall StHow BioLife’s Exclusive Qkine Cytokine Deal Could Rewire the BLFS Cell and Gene Therapy StoryBioLife Solutions, Inc. announced a multi-year global distribution agreement with Qkine Limited for cytokine and growth factor products, aiming to enhance its position in the cell and gene therapy market. The deal expands BioLife’s offerings and integrates with its biopreservation tools, supporting growth in a rapidly expanding sector. The company’s strategic initiatives include opening a biopreservation center and focusing on clinical-to-commercial therapy progression.Stock TitanBioLife Solutions inks multi-year Qkine cytokine pactBioLife Solutions has entered into a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products for the cell and gene therapy (CGT) market, with exclusive worldwide distribution rights for specific products. The companies also plan to collaborate on using BioLife's proprietary CellSeal Connect vial system for packaging. According to third-party market research, the global cytokines market is estimated at $500 million annually and is projected to grow at a mid-teens compound annual rate, reaching $1 billion by 2030.PR NewswireBioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines MarketBioLife Solutions, Inc. has entered into a multi-year supply agreement with Qkine Limited to distribute cytokine and growth factor products for cell and gene therapy manufacturing, gaining exclusive worldwide distribution rights for specific products and non-exclusive rights in the broader CGT market. The companies also plan to collaborate on packaging Qkine products using BioLife's proprietary CellSeal® Connect vial system for closed system and automated workflows. The global cytokines market is currently estimated at $500 million annually and is projected to grow at a mid-teens compound annual rate, reaching $1 billion by 2030.o2h Ventureso2h Ventures invests in Qkine – once again…Qkine, an o2h Ventures portfolio company that produces high purity, animal-free growth factors, closed its oversubscribed funding round at £4.3 million. The funding will enable Qkine to expand its research work at a new facility in Cambridge and grow internationally to meet global demand. This development marks a significant step in Qkine’s growth as it establishes its new headquarters and manufacturing facility for future operations.FinSMEsQkine Raises Over £4M in FundingQkine, a Cambridge-based manufacturer of animal-free proteins, raised over £4 million in funding led by Parkwalk Advisors Ltd and Downing Ventures. The company plans to use the capital to scale its manufacturing, R&D, and commercial functions while expanding into global markets.BusinessCloudStem cell BioTech firm raises £1.5mQkine, a stem cell protein developer, closed a £1.5m Series A round. The funds will accelerate global scale-up, key hires, and expansion into East Asia, the US, Europe, and Scandinavia. The company, spun out from Cambridge in 2016, aims to become a leading global supplier of proteins for regenerative medicine.